中医药治疗胃黏膜肠上皮化生及其作用机制研究进展

王晓鸽; 王萍; 陈婷; 张敏; 唐旭东

doi:10.3969/j.issn.1671-038X.2023.09.15

中医药治疗胃黏膜肠上皮化生及其作用机制研究进展

- 1.
  河南中医药大学第一附属医院脾胃肝胆科(郑州，450000)
- 2.
  中国中医科学院西苑医院脾胃病科
- 3.
  中国中医科学院西苑医院脾胃病研究所
基金项目:
2022年度省级科技研发计划联合基金(优势学科培育类)项目(No: 222301420021); 河南省特色骨干学科中医学学科建设项目(No: STG-ZYX06-202143)

详细信息

通讯作者: 唐旭东, E-mail: txdly@sina.com

^Δ审校者

中图分类号: R735.2

收稿日期: 2023-03-11

刊出日期: 2023-09-15

Research progress on the mechanism of Traditional Chinese Medicine in the treatment of gastric intestinal metaplasia

- 1.
  Department of Spleen, Stomach and Hepatobiliary Diseases, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, 450000, China
- 2.
  Department of Spleen and Stomach Diseases, Xiyuan Hospital of China Academy of Chinese Medical Sciences
- 3.
  Institute of Spleen and Stomach Diseases, Xiyuan Hospital of China Academy of Chinese Medical Sciences

More Information

Corresponding author: TANG Xudong, E-mail: txdly@sina.com

Received Date: 11 March 2023

Publish Date: 15 September 2023

摘要

摘要: 胃黏膜肠上皮化生(gastric intestinal metaplasia，GIM)作为一种常见的胃癌前病变，是早期胃癌发生的重要风险因素。西医以根除幽门螺杆菌、保护黏膜、中和胆汁等治疗为主，缺乏可直接阻断或者逆转GIM进展的药物，大量临床研究表明中医药治疗GIM在改善临床症状、黏膜病理及胃功能方面具有一定作用，但其作用机制尚未完全阐明，本文检索并整理近年来中医药治疗GIM的相关文献，从炎症、细胞凋亡与增殖、微血管增殖等角度深入挖掘其作用机制，并分析问题与不足，为中医药治疗GIM的临床及分子生物学研究提供科学依据。
- 胃黏膜肠上皮化生 /
- 中医药 /
- 机制 /
- 炎症 /
- 细胞凋亡 /
- 微血管增殖
Abstract: As a common gastric precancerous lesion, gastric intestinal metaplasia(GIM) is an important risk factor for the occurrence of early gastric cancer. Western medicine focuses on Hp eradication, mucosa protection, and bile neutralization, but lacks drugs that progression of GIM. A large number of clinical studies have shown that the treatment of GIM with Traditional Chinese Medicine has a certain effect in improving clinical symptoms, mucosal pathology and gastric function, but its mechanism of action has not been fully clarified. Literature on the treatment of GIM with Traditional Chinese Medicine in recent years was retrieved and sorted out. From the perspectives of inflammation, cell apoptosis and proliferation, microvascular proliferation and other aspects, the mechanism of its action was deeply explored, and the defects and deficiencies were analyzed to provide scientific basis for clinical and molecular biological research on the treatment of GIM by Traditional Chinese Medicine.
- gastric intestinal metaplasia /
- Traditional Chinese Medicine /
- mechanism /
- inflammation /
- apoptosis /
- microangiogenesis

HTML全文

参考文献(45)

[1]	曹毛毛, 陈万青. GLOBOCAN 2020全球癌症统计数据解读[J]. 中国医学前沿杂志(电子版), 2021, 13(3): 63-69. https://www.cnki.com.cn/Article/CJFDTOTAL-YXQY202103010.htm
[2]	曹毛毛, 李贺, 孙殿钦, 等. 2000—2019年中国胃癌流行病学趋势分析[J]. 中华消化外科杂志, 2021, 20(1): 102-109. doi: 10.3760/cma.j.cn115610-20201130-00746
[3]	国家消化系疾病临床医学研究中心(上海), 国家消化道早癌防治中心联盟(GECA), 中华医学会消化病学分会幽门螺杆菌学组, 等. 中国胃黏膜癌前状态及病变的处理策略专家共识(2020)[J]. 中华消化内镜杂志, 2020, 37(11): 769-780. doi: 10.3760/cma.j.cn321463-20200916-00776
[4]	Correa P. A human model of gastric carcinogenesis[J]. Cancer Res, 1988, 48(13): 3554-3560.
[5]	Lee JWJ, Zhu F, Srivastava S, et al. Severity of gastric intestinal metaplasia predicts the risk of gastric cancer: a prospective multicentre cohort study(GCEP)[J]. Gut, 2022, 71(5): 854-863. doi: 10.1136/gutjnl-2021-324057
[6]	李海文, 张伟健, 许艺飞, 等. 肠上皮化生和胃癌发生关系的研究进展[J]. 中华中医药杂志, 2021, 36(1): 311-315. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY202101081.htm
[7]	李军祥, 陈誩, 吕宾, 等. 慢性萎缩性胃炎中西医结合诊疗共识意见(2017年)[J]. 中国中西医结合消化杂志, 2018, 26(2): 121-131. https://zxyxh.whuhzzs.com/article/doi/10.3969/j.issn.1671-038X.2018.02.03
[8]	Cao Y, Zheng YX, Niu JB, et al. Efficacy of Banxia Xiexin Decoction for chronic atrophic gastritis: a systematic review and meta-analysis[J]. PLoS One, 2020, 15(10): e0241202. doi: 10.1371/journal.pone.0241202
[9]	邓鑫, 叶晖, 成虹, 等. 六君子加减方治疗慢性萎缩性胃炎伴肠上皮化生脾胃虚弱证随机对照临床研究[J]. 中国中西医结合杂志, 2021, 41(8): 901-906. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXJ202108001.htm
[10]	李紫昕, 戈焰. 猴菇和胃颗粒治疗慢性萎缩性胃炎伴不同类型肠上皮化生的临床疗效[J]. 内蒙古中医药, 2022, 41(1): 3-4. https://www.cnki.com.cn/Article/CJFDTOTAL-NZYY202201002.htm
[11]	吴绵勇, 郁银娟. 清热祛湿方加减联合西药治疗脾胃湿热型慢性萎缩性胃炎伴肠上皮化生临床研究[J]. 新中医, 2020, 52(8): 69-72. https://www.cnki.com.cn/Article/CJFDTOTAL-REND202008024.htm
[12]	李阅桥, 徐永居. 胶体果胶铋胶囊联合自拟益气肠化方改善萎缩性胃炎伴肠上皮化生患者胃功能指标的效果[J]. 实用临床医药杂志, 2019, 23(12): 75-78, 82. https://www.cnki.com.cn/Article/CJFDTOTAL-XYZL201912022.htm
[13]	刘军, 钱赟达, 黄永宏, 等. 肠化方加减联合西药治疗慢性萎缩性胃炎伴肠上皮化生临床研究[J]. 新中医, 2022, 54(4): 68-71. https://www.cnki.com.cn/Article/CJFDTOTAL-REND202204017.htm
[14]	章燕红, 韩丰, 冀子中, 等. 慢性萎缩性胃炎伴肠上皮化生与胃泌素-17胃蛋白酶原及幽门螺杆菌感染的关系[J]. 中国药物与临床, 2022, 22(5): 415-418. https://www.cnki.com.cn/Article/CJFDTOTAL-YWLC202205007.htm
[15]	姚鹏, 田晶晶, 康洪昌, 等. 荜铃胃痛颗粒联合标准四联疗法治疗慢性萎缩性胃炎伴轻中度肠上皮化生患者的效果研究[J]. 中国中西医结合外科杂志, 2021, 27(6): 855-859. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZX202106014.htm
[16]	王艳艳, 孙明祎. 健脾活血解毒法治疗慢性萎缩性胃炎伴胃黏膜肠上皮化生[J]. 长春中医药大学学报, 2019, 35(6): 1089-1091. https://www.cnki.com.cn/Article/CJFDTOTAL-CZXX201906022.htm
[17]	Zhang J, Wang HH. Morroniside protects against chronic atrophic gastritis in rat via inhibiting inflammation and apoptosis[J]. Am J Transl Res, 2019, 11(9): 6016-6023.
[18]	路伟伟. 加味黄芪建中汤治疗慢性萎缩性胃炎伴肠上皮化生[J]. 中医学报, 2019, 34(7): 1531-1534. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZK201907041.htm
[19]	Liu QS, Tang JY, Chen SL, et al. Berberine for gastric cancer prevention and treatment: multi-step actions on the Correa's cascade underlie its therapeutic effects[J]. Pharmacol Res, 2022, 184: 106440.
[20]	郭越, 刘辉华, 黄瑞. 石斛养胃祛萎合剂辨治慢性萎缩性胃炎合并肠上皮化生患者52例[J]. 环球中医药, 2021, 14(2): 340-344. https://www.cnki.com.cn/Article/CJFDTOTAL-HQZY202102041.htm
[21]	Li Y, Li T, Chen JN, et al. Manpixiao Decoction halted the malignant transformation of precancerous lesions of gastric cancer: from network prediction to In-vivo verification[J]. Front Pharmacol, 2022, 13: 927731.
[22]	Koide T, Koyanagi-Aoi M, Uehara K, et al. CDX2-induced intestinal metaplasia in human gastric organoids derived from induced pluripotent stem cells[J]. Science, 2022, 25(5): 104314.
[23]	Li YX, Jiang LB, Li ZC, et al. Differences in gastric microbiota and mucosal function between patients with chronic superficial gastritis and intestinal metaplasia[J]. Front Microbiol, 2022, 13: 950325.
[24]	林贞妍, 冯小可, 崔国良, 等. 猪苓多糖对胃肠上皮化生细胞模型的影响[J]. 中国中西医结合消化杂志, 2021, 29(1): 8-13. https://zxyxh.whuhzzs.com/article/doi/10.3969/j.issn.1671-038X.2021.01.02
[25]	李亚博. 理气活血解毒法对慢性萎缩性胃炎伴肠上皮化生的临床研究及机制探讨[D]. 北京: 北京中医药大学, 2017.
[26]	Han LP, Li T, Wang YY, et al. Weierning, a Chinese patent medicine, improves chronic atrophic gastritis with intestinal metaplasia[J]. J Ethnopharmacol, 2023, 309: 116345.
[27]	Kwon SK, Park JC, Kim KH, et al. Human gastric microbiota transplantation recapitulates premalignant lesions in germ-free mice[J]. Gut, 2022, 71(7): 1266-1276.
[28]	Wu Y, Li Y, Jin XM, et al. Effects of Granule Dendrobii on chronic atrophic gastritis induced by N-methyl-N'-nitro-N-nitrosoguanidine in rats[J]. World J Gastroenterol, 2022, 28(32): 4668-4680.
[29]	刘伟. 胃痞灵调控mTOR/HIF-1 α/SIRT6信号通路介导胃癌前病变有氧糖酵解的分子机制研究[D]. 广州: 广州中医药大学, 2019.
[30]	龙华晴, 吴人照, 马津真, 等. 铁皮枫斗颗粒组方药物对慢性萎缩性胃炎大鼠胃黏膜萎缩的逆转作用及PCNA、Bcl-2表达的影响[J]. 中国中医药科技, 2018, 25(4): 498-501. https://www.cnki.com.cn/Article/CJFDTOTAL-TJYY201804013.htm
[31]	宋斌, 段文芳, 唐磊, 等. 突变型p53与NF-κB在肿瘤发生中的相互作用[J]. 中国细胞生物学学报, 2020, 42(6): 1113-1120. https://www.cnki.com.cn/Article/CJFDTOTAL-XBZZ202006021.htm
[32]	杨小军, 田锋亮, 刘宇, 等. 益胃消瘀颗粒对胃黏膜肠化大鼠及相关炎症介质的影响[J]. 世界中西医结合杂志, 2019, 14(2): 198-202. https://www.cnki.com.cn/Article/CJFDTOTAL-SJZX201902056.htm
[33]	Pan RQ, Ryan J, Pan D, et al. Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis[J]. Cell, 2022, 185(9): 1521-1538.e18.
[34]	张升波, 刘伟, 张晨. 汉防己乙素通过调节NF-κB信号通路对胃癌前病变大鼠的作用研究[J]. 临床和实验医学杂志, 2021, 20(16): 1685-1689. https://www.cnki.com.cn/Article/CJFDTOTAL-SYLC202116002.htm
[35]	Faldt Beding A, Larsson P, Helou K, et al. Pan-cancer analysis identifies BIRC5 as a prognostic biomarker[J]. BMC Cancer, 2022, 22(1): 322.
[36]	田锋亮, 李延萍, 杨小军, 等. 益胃消瘀颗粒改善大鼠胃黏膜肠上皮化生的作用研究[J]. 重庆医学, 2018, 47(32): 4102-4106, 4111. https://www.cnki.com.cn/Article/CJFDTOTAL-CQYX201832005.htm
[37]	Lv SB, Chen XD, Chen Y, et al. Ginsenoside Rg3 induces apoptosis and inhibits proliferation by down-regulating TIGAR in rats with gastric precancerous lesions[J]. BMC Complement Med Ther, 2022, 22(1): 188.
[38]	Zhang XL, Zheng ZL, Shin YK, et al. Angiogenic factor thymidine phosphorylase associates with angiogenesis and lymphangiogenesis in the intestinal-type gastric cancer[J]. Pathology, 2014, 46(4): 316-324.
[39]	Gao Y, Wang JD, Zhao MY, et al. Atractylenolide Ⅲ attenuates angiogenesis in gastric precancerous lesions through the downregulation of delta-like ligand 4[J]. Front Pharmacol, 2022, 13: 797805.
[40]	Tirpe AA, Gulei D, Ciortea SM, et al. Hypoxia: overview on hypoxia-mediated mechanisms with a focus on the role of HIF genes[J]. Int J Mol Sci, 2019, 20(24): 6140.
[41]	Rey S, Schito L, Wouters BG, et al. Targeting hypoxia-inducible factors for antiangiogenic cancer therapy[J]. Trends Cancer, 2017, 3(7): 529-541.
[42]	Zhao WX, Liu ZF, Li XL, et al. Correlations of serum homocysteine, VEGF and gastrin 17 with gastric cancer and precancerous lesions[J]. Eur Rev Med Pharmacol Sci, 2019, 23(10): 4192-4198.
[43]	Zeng ZZ, Nian Q, Chen NZ, et al. Ginsenoside Rg3 inhibits angiogenesis in gastric precancerous lesions through downregulation of Glut1 and Glut4[J]. Biomed Pharmacother, 2022, 145: 112086.
[44]	Liu W, Pan HF, Yang LJ, et al. Panax ginseng C.A. Meyer(Rg₃)ameliorates gastric precancerous lesions in Atp4a^-/-mice via inhibition of glycolysis through PI3K/AKT/miRNA-21 pathway[J]. Evid Based Complement Alternat Med, 2020, 2020: 2672648.
[45]	Bian YQ, Chen X, Cao HY, et al. A correlational study of Weifuchun and its clinical effect on intestinal flora in precancerous lesions of gastric cancer[J]. Chin Med, 2021, 16(1): 120.